Press release
Duchenne Muscular Dystrophy Transcriptomic Profiling Market to Reach USD 2,277.8 Million by 2036, Expanding at 10.8% CAGR as Gene Therapy Monitoring and RNA Biomarker Discovery Accelerate
Duchenne Muscular Dystrophy Transcriptomic Profiling Market
Get detailed market forecasts, competitive benchmarking, and pricing trends: https://www.factmr.com/connectus/sample?flag=S&rep_id=15618
The market was valued at USD 737.2 million in 2025 and is expected to create an absolute opportunity of USD 1,461.0 million by 2036. As gene therapies and disease-modifying treatments advance, pharmaceutical developers, specialist laboratories, and research institutions are increasingly relying on RNA-based profiling to measure treatment response and improve patient stratification.
Key Market Highlights at a Glance
• Market value in 2025: USD 737.2 million
• Market value in 2026: USD 816.8 million
• Forecast market value by 2036: USD 2,277.8 million
• Forecast CAGR (2026-2036): 10.8%
• Absolute opportunity through 2036: USD 1,461.0 million
• Leading technology segment: RNA Sequencing (RNA-Seq) - 30.0% share
• Leading application segment: Biomarker Discovery - 30.0% share
• Leading sample type segment: Skeletal Muscle Biopsy - 30.0% share
• Leading end-user segment: Pharmaceutical & Biotechnology Companies - 30.0% share
• Fastest-growing country: Germany - 14.6% CAGR
• Countries analyzed:
o Germany: 14.6%
o Brazil: 13.5%
o USA: 12.4%
o South Korea: 11.3%
o United Kingdom: 10.3%
o Japan: 9.2%
Why Is the Duchenne Muscular Dystrophy Transcriptomic Profiling Market Growing?
The market is experiencing strong momentum as RNA-based technologies become critical tools for evaluating therapeutic efficacy, understanding disease biology, and supporting regulatory decision-making.
Key Growth Drivers
• Gene therapy, exon-skipping therapies, and anti-inflammatory treatment programs increasingly require transcriptomic evidence to assess biological response.
• Biomarker-driven clinical trials are expanding across DMD treatment development programs and post-approval monitoring initiatives.
• RNA profiling supports mutation-independent treatment response tracking across diverse patient populations.
• Single-cell and spatial transcriptomic technologies are enabling deeper analysis of small muscle tissue samples.
• Increased regulatory focus on long-term safety monitoring is raising demand for repeat transcriptomic assessments.
Unlock 360° insights for strategic decision making and investment planning: https://www.factmr.com/checkout/15618
Expert Analyst Commentary
Shambhu Nath Jha, Senior Analyst at Fact.MR, stated:
"Duchenne muscular dystrophy research now goes beyond finding the gene change. RNA testing helps researchers see how treatment affects muscle and immune activity. Methods that work with small tissue samples are likely to receive greater use. They must also compare patients who begin treatment at different stages and show whether RNA changes match improvements seen during clinical checks."
Which Technology Segment Leads Market Share?
RNA Sequencing (RNA-Seq) Dominates with 30.0% Share
RNA Sequencing (RNA-Seq) is expected to hold 30.0% market share in 2026, making it the leading technology category.
The technology provides comprehensive visibility into gene expression, splicing abnormalities, and therapeutic response patterns across DMD samples. RNA-Seq remains the preferred approach for evaluating treatment-related molecular changes in both clinical trials and translational research.
Technology Segment Highlights
• RNA Sequencing (RNA-Seq): 30.0% share
• Broad application in expression and splicing analysis
• Supports treatment response monitoring
• Enables comparison between disease activity and therapeutic outcomes
• Foundation technology for advanced transcriptomic workflows
Other technologies include:
• Bulk Transcriptomics
• Single-Cell Transcriptomics
• Spatial Transcriptomics
Why Does Biomarker Discovery Lead Applications?
Biomarker Discovery Captures 30.0% Market Share
Biomarker Discovery is projected to account for 30.0% share in 2026, making it the largest application segment.
As therapy developers seek measurable indicators of treatment effectiveness, transcriptomic biomarkers are becoming increasingly important for patient selection, dose optimization, and regulatory submissions.
Application Highlights
• Biomarker Discovery: 30.0% share
• Supports patient selection
• Enables therapy response assessment
• Assists dose optimization
• Facilitates regulatory evidence generation
Additional application areas include:
• Disease Progression Monitoring
• Drug Development & Clinical Trials
• Patient Stratification
Which Sample Type Leads Transcriptomic Profiling Demand?
Skeletal Muscle Biopsy Leads with 30.0% Share
Skeletal Muscle Biopsy is expected to capture 30.0% market share in 2026.
Direct muscle tissue sampling provides the clearest evidence of dystrophin-related expression changes, inflammation, fibrosis, and treatment response, making it central to DMD transcriptomic studies.
Sample Type Highlights
• Skeletal Muscle Biopsy: 30.0% share
• Direct assessment of affected tissue
• Supports dystrophin-pathway analysis
• Critical for validating blood-based findings
• Widely used in clinical development programs
Other sample types include:
• Blood Samples
• Tissue-Derived RNA
• Cell Models
Gain Full Access to Market Forecasts and Key Drivers: https://www.factmr.com/report/duchenne-muscular-dystrophy-transcriptomic-profiling-market
Why Do Pharmaceutical & Biotechnology Companies Lead End-User Demand?
Pharmaceutical & Biotechnology Companies Hold 30.0% Share
Pharmaceutical and biotechnology companies are projected to represent 30.0% of total demand in 2026.
These organizations increasingly use transcriptomic profiling for target identification, biomarker validation, therapy monitoring, patient stratification, and regulatory support.
Market Dynamics
Market Drivers
• Post-approval biomarker monitoring for gene therapies
• Mutation-independent response measurement
• Expansion of gene therapy and exon-skipping pipelines
• Single-cell technologies overcoming tissue limitations
• Natural-history datasets supporting external control studies
Market Restraints
• Limited availability of skeletal muscle biopsy samples
• Biological variability related to age, steroid exposure, and fibrosis
• Institutional staffing and monitoring capacity constraints
• Cross-site validation and data transfer challenges
Regional and Country Outlook
Country Growth Rates (2026-2036)
• Germany: 14.6% CAGR
• Brazil: 13.5% CAGR
• USA: 12.4% CAGR
• South Korea: 11.3% CAGR
• United Kingdom: 10.3% CAGR
• Japan: 9.2% CAGR
Competitive Landscape
Leading Market Participants
• Sarepta Therapeutics, Inc. - Leader in DMD gene therapy through Elevidys
• F. Hoffmann-La Roche Ltd. - Strong rare disease and neuromuscular portfolio
• Solid Biosciences Inc. - Advancing gene therapy development programs
• REGENXBIO Inc. - Developing RGX-202 through the AFFINITY DUCHENNE program
• Illumina, Inc. - Global sequencing technology leader
• Thermo Fisher Scientific Inc. - Integrated transcriptomic workflow solutions
• QIAGEN N.V. - Sample preparation and molecular analysis expertise
• Revvity, Inc. - Research testing and diagnostic support capabilities
• 10x Genomics - Single-cell and spatial transcriptomics innovation
• Bruker - Advanced molecular analysis technologies
Market competition is increasingly driven by sequencing capabilities, biomarker-development expertise, gene therapy monitoring solutions, transcriptomic workflow standardization, and integration of single-cell and spatial analysis technologies.
Discover the Latest Insights in the Healthcare Industry: https://www.factmr.com/industry/healthcare
Frequently Asked Questions (FAQ)
What is the projected size of the Duchenne Muscular Dystrophy Transcriptomic Profiling Market by 2036?
The Duchenne Muscular Dystrophy Transcriptomic Profiling Market is projected to reach USD 2,277.8 million by 2036, up from USD 816.8 million in 2026.
What is the CAGR of the Duchenne Muscular Dystrophy Transcriptomic Profiling Market?
The Duchenne Muscular Dystrophy Transcriptomic Profiling Market is forecast to grow at a 10.8% CAGR from 2026 to 2036.
Which technology segment leads the market?
RNA Sequencing (RNA-Seq) is expected to lead the market with a 30.0% share in 2026.
Which application segment holds the largest market share?
Biomarker Discovery is projected to account for 30.0% of global market revenue in 2026.
Top Trending Reports:
Spinal Bulbar Muscular Atrophy Treatment Market: https://www.factmr.com/report/1221/spinal-bulbar-muscular-atrophy-treatment-market
Cancer Profiling Market: https://www.factmr.com/report/358/cancer-profiling-market
Cancer Tumor Profiling Market: https://www.factmr.com/report/cancer-tumor-profiling-market
RNA Transcriptome Profiling Test Market: https://www.factmr.com/report/3113/rna-transcriptome-profiling-test-market
- Contact Us -
11140 Rockville Pike, Suite 400, Rockville,
MD 20852, United States
Tel: +1 (628) 251-1583 | sales@factmr.com
About Fact.MR
Fact.MR is a global market research and consulting firm, trusted by Fortune 500 companies and emerging businesses for reliable insights and strategic intelligence. With a presence across the U.S., UK, India, and Dubai, we deliver data-driven research and tailored consulting solutions across 30+ industries and 1,000+ markets. Backed by deep expertise and advanced analytics, Fact.MR helps organizations uncover opportunities, reduce risks, and make informed decisions for sustainable growth.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Duchenne Muscular Dystrophy Transcriptomic Profiling Market to Reach USD 2,277.8 Million by 2036, Expanding at 10.8% CAGR as Gene Therapy Monitoring and RNA Biomarker Discovery Accelerate here
News-ID: 4583177 • Views: …
More Releases from Fact.MR
HBM for Defense and Space Computing Market is Projected to increase from USD 1.8 …
The global HBM for Defense and Space Computing Market reached USD 1.5 billion in 2025 and is projected to increase from USD 1.8 billion in 2026 to USD 9.0 billion by 2036, registering a compound annual growth rate (CAGR) of 17.4% from 2026 to 2036, according to Fact.MR.
Get Detailed Market Forecasts, Competitive Benchmarking, and Pricing Trends: https://www.factmr.com/connectus/sample?flag=S&rep_id=16012
The growing use of artificial intelligence and high-performance computing in defense and space…
HBM CoWoS Packaging Capacity and Supply Demand Market Will Hit USD 32.6 billion …
The global HBM CoWoS Packaging Capacity and Supply Demand Market reached USD 6.4 billion in 2025 and is projected to increase from USD 7.4 billion in 2026 to USD 32.6 billion by 2036, registering a compound annual growth rate (CAGR) of 16.0% from 2026 to 2036, according to Fact.MR.
Get Detailed Market Forecasts, Competitive Benchmarking, and Pricing Trends: https://www.factmr.com/connectus/sample?flag=S&rep_id=16008
The rapid expansion of artificial intelligence workloads is increasing demand for high-performance computing…
Agentic Artificial Intelligence Applications in Vector Database Market is Valued …
The global Agentic Artificial Intelligence Applications in Vector Database Market reached USD 2.3 billion in 2025 and is projected to increase from USD 2.8 billion in 2026 to USD 18.7 billion by 2036, registering a compound annual growth rate (CAGR) of 20.9% from 2026 to 2036, according to Fact.MR.
Get Detailed Market Forecasts, Competitive Benchmarking, and Pricing Trends: https://www.factmr.com/connectus/sample?flag=S&rep_id=16000
Agentic AI applications increasingly require systems capable of storing, retrieving, and interpreting high-dimensional…
AI Training Data Licensing & Royalty Brokerage Services Market Forecasted 31.1% …
The global AI Training Data Licensing and Royalty Brokerage Services Market surpassed USD 2.3 billion in 2025 and is projected to increase from USD 3.0 billion in 2026 to USD 45.0 billion by 2036, registering a compound annual growth rate (CAGR) of 31.1% from 2026 to 2036, according to Fact.MR. The transition from web scraping toward paid content access and structured royalty routing is creating significant demand for licensing and…
More Releases for RNA
Small Interfering RNA (siRNA) Therapeutics Market Growth (2026-2033) | RNA Drugs …
DataM Intelligence has released a new research report titled "Small Interfering RNA (siRNA) Therapeutics Market Size 2026" The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market…
CD Formulation Launches Custom Circular RNA Synthesis Service to Accelerate RNA …
CD Formulation introduces a customizable circRNA synthesis service, delivering high-quality, stable circRNAs for therapeutics, vaccines, and gene research, supported by advanced design and QC processes.
CD Formulation, a leading provider of advanced small nucleic acid synthesis [https://www.formulationbio.com/nucleic-acid/custom-small-nucleic-acid-synthesis.html] solutions, is proud to announce the launch of its fully customizable circular RNA (circRNA) synthesis service. This new service addresses the growing need for stable, non-immunogenic RNA molecules for therapeutic development, vaccine research, and…
Self-Amplifying RNA Synthesis Market Gains Traction as Biotech Firms Embrace Sca …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Self-Amplifying RNA Synthesis Market- (By Product & Service (Products (Enzymes & Reagents, Premade saRNA, Others), Custom Synthesis Services), By Application (Therapeutics Development (Oncology, Infectious Diseases, Others), Biomedical Research), By End-User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According to the latest research by InsightAce Analytic,…
RNA Extraction and RNA Purification Market: Growth, Trends & Competitive Landsca …
The global RNA Extraction and RNA Purification Market is expected to grow at 6.3% CAGR from 2025 to 2032.
This Market Report is the result of extensive research and analysis conducted by our team of experienced market researchers through -
• 70% efforts of Primary Research
• 15% efforts of Secondary Research
• 15% efforts from the subscription to Paid database providing industry overview, macro and micro economics factors, and financials of private limited…
RNA Targeting Small Molecules Therapeutics Market: Exponential Growth with Risin …
Estimations Predict a CAGR of 29.8% by 2029 in Global RNA Targeting Small Molecules Therapeutics Market Boosted by Precision Medicine, RNA Biomarker Identification and RNA Genetic Manipulation
What Is The Projected Market Size of The Global RNA Targeting Small Molecules Therapeutics Market And Its Growth Rate?
• The market will grow from $6.1 billion in 2024 to $7.87 billion in 2025 at a compound annual growth rate (CAGR) of 28.9%.
• Expected exponential…
Global DNARNA Extraction Kit Market by Type (Cell-free DNA (cfDNA), Sequence-spe …
"DNARNA Extraction Kit Market" is segmented by Company, Region (country), By Type, Application, stakeholders and other participants. This report provides an analysis of revenue and forecast across Type and Application segments for 2023-2032.
The market for DNARNA Extraction Kits has been thoroughly researched via primary and secondary sources to produce this research study. Along with a competitive analysis of the market, segmented by application, type, and geographical trends, it offers a…
